Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Center, Open-label, Non-comparative, Phase I/II Clinical Trial to Assess the MTD, Safety and Efficacy of BEY1107 in Monotherapy and in Combination with Gemcitabine in Patient with Locally Advanced or Metastatic Pancreatic Cancer

NCT03579836 is registered in ClinicalTrials.gov with BeyondBio Inc. as lead sponsor.

NCT NCT03579836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03579836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Center, Open-label, Non-comparative, Phase I/II Clinical Trial to Assess the MTD, Safety and Efficacy of BEY1107 in Monotherapy and in Combination with Gemcitabine in Patient with Locally Advanced or Metastatic Pancreatic Cancer
Lead sponsor
BeyondBio Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 14, 2018
Completion date
December 31, 2026
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic pancreatic cancer